Long-acting octreotide for advanced liver cancer: A well-designed negative trial - Commentary

Jonathan Schwartz

doi:10.1097/EBG.0b013e31805d27f9

Long-acting octreotide for advanced liver cancer: A well-designed negative trial - Commentary

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	43-44
Number of pages	2
Journal	Evidence-Based Gastroenterology
Volume	8
Issue number	2
DOIs	https://doi.org/10.1097/EBG.0b013e31805d27f9
State	Published - May 1 2007
Externally published	Yes

ASJC Scopus subject areas

Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/EBG.0b013e31805d27f9

Cite this

@article{42869fb000de430d89b90c386a476773,

title = "Long-acting octreotide for advanced liver cancer: A well-designed negative trial - Commentary",

author = "Jonathan Schwartz",

year = "2007",

month = may,

day = "1",

doi = "10.1097/EBG.0b013e31805d27f9",

language = "English (US)",

volume = "8",

pages = "43--44",

journal = "Evidence-Based Gastroenterology",

issn = "1527-8557",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Long-acting octreotide for advanced liver cancer

T2 - A well-designed negative trial - Commentary

AU - Schwartz, Jonathan

PY - 2007/5/1

Y1 - 2007/5/1

UR - http://www.scopus.com/inward/record.url?scp=34247890050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247890050&partnerID=8YFLogxK

U2 - 10.1097/EBG.0b013e31805d27f9

DO - 10.1097/EBG.0b013e31805d27f9

M3 - Comment/debate

AN - SCOPUS:34247890050

SN - 1527-8557

VL - 8

SP - 43

EP - 44

JO - Evidence-Based Gastroenterology

JF - Evidence-Based Gastroenterology

IS - 2

ER -

Long-acting octreotide for advanced liver cancer: A well-designed negative trial - Commentary

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this